- Another four U.S. hospitals have deployed G Medical Innovations’ (GMV) independent diagnostic testing facilities (IDTF) platform
- The platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely
- Now, ten U.S. universities have deployed the digital health company’s IDTF platform in the treatment phase, meaning they’re actively enrolling and treating patients using GMV’s service
- The uptake means the number of patients monitored with IDTF has also risen — just under 4000 patients were enrolled using the service over July
- Compared to last year’s statistics, GMV is confident there’ll be a three-fold increase in active patient enrollments using IDTF over 2020
- On Monday’s market open, GMV shares are up 4.88 per cent, trading for 4.3 cents
Another four U.S. hospitals have deployed G Medical Innovations’ (GMV) independent diagnostic testing facilities (IDTF) platform.
The digital health company’s platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely.
GMV’s flagship offering includes the Prizma device, a medical smartphone case, and the G Medical Patch, another tool for monitoring vital signs.
Now, ten U.S. universities have deployed the IDTF platform in the treatment phase, meaning they’re actively enrolling and treating patients using the GMV service.
The uptake means the number of patients monitored with IDTF has also risen — just under 4000 patients were enrolled using the service over July. Compared to 27,946 patients enrolled last year, GMV is confident there’ll be a three-fold increase in active patient enrollments monitored using IDTF over 2020.
In addition, G Medical says seven hospitals have completed IDTF’s evaluation phase. Now, they’re finalising the platform’s implementation stage, and GMV is targeting deployment across those hospitals throughout next month.
“The uptake that we are witnessing of our IDTF platform in the U.S. hospital sector is excellent,” said GMV Chief Dr Yacov Geva.
“We are confident that these new deployments will add to the growing patient enrolments we are witnessing from initial partners, providing G Medical with further diversified, stable revenue,” he continued.
“The addressable market for our remote patient monitoring services is currently valued at US$6.61 billion (around A$9.23 billion) and is expected to grow to over US$17 billion (around A$23.74 billion) by 2026. This highlights the considerable upside potential that G Medical can pursue through its established infrastructure and reliable service offering in the near future,” Yaacov concluded.
On Monday’s market open, GMV shares are trading 4.88 per cent higher for 4.3 cents at 10:15 am AEST.